Get the Stockscreener App
45.57
0.73%
0.33
After Hours:
45.57
Qiagen Nv stock is traded at $45.57, with a volume of 699.01K.
It is up +0.73% in the last 24 hours and down -0.31% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
See More
Previous Close:
$45.24
Open:
$45.37
24h Volume:
699.01K
Relative Volume:
0.60
Market Cap:
$10.07B
Revenue:
$1.94B
Net Income/Loss:
$72.70M
P/E Ratio:
31.43
EPS:
1.45
Net Cash Flow:
$405.21M
1W Performance:
+2.50%
1M Performance:
-0.31%
6M Performance:
+6.00%
1Y Performance:
+9.11%
1-Day Range:
$45.08
$45.62
1-Week Range:
$44.10
$46.08
52-Week Range:
$35.83
$47.44
Qiagen Nv Stock (QGEN) Company Profile
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology - GlobeNewswire
QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology - StockTitan
Qiagen (NYSE:QGEN) Short Interest Up 17.4% in September - MarketBeat
QIAGEN Stock Likely to Gain From PreAnalytiX's Newly Launched PAXgene - MSN
QIAGEN (QGEN) Launches QIAcuity Kits and Software Update - MSN
Marshall Wace LLP Sells 207,630 Shares of Qiagen (NYSE:QGEN) - MarketBeat
Those who invested in Qiagen (NYSE:QGEN) five years ago are up 41% - Yahoo Finance
Qiagen secures EU IVDR certification for QIAstat-Dx systems and panels - Medical Device Network
Protein Expression Market Industry Trends and Global Forecasts to 2035: Since 2023, Over 6,500 Patents Related to Protein Expression have been Granted - GlobeNewswire Inc.
QGEN Stock to Gain From New IVDR Win for QIAstat-Dx Systems and Panels - Yahoo Finance
Global MicroRNA Market Size Projected to Reach USD 7.7 Billion by 2032, with 21.1% CAGR – SNS Insider - GlobeNewswire Inc.
QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays - XM
QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays - The Manila Times
QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays - GlobeNewswire
QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays - StockTitan
QGEN Stock Might Rise on Partnership With Bode for GEDmatch PRO - MSN
QIAGEN Stock Likely to Gain From PreAnalytiX's Newly Launched PAXgene - Zacks Investment Research
QIAGEN Stock Likely to Gain From PreAnalytiX's Newly Launched PAXgene - Yahoo Finance
Oxidative Stress Analysis Market Current Scope – Abcam, Enzo Biochem, Merck, Qiagen NV - Cauverynews
Point72 Asset Management L.P. Has $48.68 Million Stock Position in Qiagen (NYSE:QGEN) - MarketBeat
PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples - XM
PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples - GlobeNewswire
PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples - StockTitan
QIAGEN Selects Bode as GEDmatch PRO Database Partner - Forensic
Axa S.A. Has $225.59 Million Holdings in Zoetis Inc. (NYSE:ZTS) - Defense World
Japan’s health regulator MHLW approves five new medications - World Pharmaceutical Frontiers
Frank Rimerman Advisors LLC Takes Position in Qiagen (NYSE:QGEN) - Defense World
Qiagen (NYSE:QGEN) Shares Bought by Envestnet Asset Management Inc. - Defense World
Point72 Europe London LLP Has $19.87 Million Position in Qiagen (NYSE:QGEN) - MarketBeat
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 32% Undervalued - Simply Wall St
Global Multiomics Market Set for Rapid Growth and Trend by 2024-2031 Key Drivers And Analysis – Bruker, QIAGEN - EIN News
QGEN Stock Might Rise on Partnership With Bode for GEDmatch PRO - Yahoo Finance
XTX Topco Ltd Makes New $569,000 Investment in QuidelOrtho Co. (NASDAQ:QDEL) - Defense World
QIAGEN NV : Berenberg reiterates its Buy rating - Marketscreener.com
Kenya Airways rolls out campaign to woo Chinese tourists - The Star Kenya
Objective long/short (QGEN) Report - Stock Traders Daily
Qiagen (NYSE:QGEN) Shares Purchased by Vanguard Personalized Indexing Management LLC - Defense World
Quadient: launch of a share buyback program - Marketscreener.com
Qiagen Bode Technology Would Become Exclusive Global Commercial Partner For GEDmatch Pro Genealogy Database - XM
QIAGEN and Bode Technology partner to advance use of GEDmatch PRO forensic genetic genealogy database - GlobeNewswire
QIAGEN and Bode Technology partner to advance use of GEDmatch PRO forensic genetic genealogy database - StockTitan
Quadient launches share buyback program for up to €30 million - GlobeNewswire
Fremantle's Áine Tighe ruled out for remainder of AFLW season with ACL injury - The42
Kenya Airways expands further into Chinese market - Getaway Magazine
AFLW injury update: Áine Tighe - Fremantle Dockers
Sei Investments Co. Grows Stock Holdings in Qiagen (NYSE:QGEN) - Defense World
'Hopefully, I can build from here' – Chloe Dygert wants to combine health with her mental resilience in 2025 - Cyclingnews
Mutual of America Capital Management LLC Trims Stock Position in Qualys, Inc. (NASDAQ:QLYS) - Defense World
State of New Jersey Common Pension Fund D Cuts Stock Holdings in Qualys, Inc. (NASDAQ:QLYS) - Defense World
CTV National News: Zoos push for conservation - CTV News
Davidson Capital Management Inc. Boosts Holdings in Qualys, Inc. (NASDAQ:QLYS) - Defense World
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
1.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):